EoCene Ltd. (EOCN) stock
EOCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.46−0.07 (-2.77%)
Close on Nov 17, 2026Market cap $2.46MP/E –Yield –
EoCene EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
EoCene's EPS for the twelve months ending Dec 31, 2025 was $19.12, down 70.4% year over year. For fiscal 2025 it was $19.12, down 70.4% from the year before. The highest annual figure on record is $1900.80 in fiscal 2021.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $19.12 | -70.4% |
| FY2024 | Dec 31, 2024 | $64.64 | -73.1% |
| FY2023 | Dec 31, 2023 | $240.00 | -76.5% |
| FY2022 | Dec 31, 2022 | $1022.40 | -46.2% |
| FY2021 | Dec 31, 2021 | $1900.80 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.86 | – |
| Q4 FY2025 | Dec 31, 2025 | -$6.41 | -134.7% |
| Q3 FY2025 | Sep 30, 2025 | $2.64 | -80.0% |
| Q2 FY2025 | Jun 30, 2025 | $5.06 | -94.5% |
| Q4 FY2024 | Dec 31, 2024 | -$15.97 | -107.4% |
| Q3 FY2024 | Sep 30, 2024 | $18.48 | -96.1% |
| Q2 FY2024 | Jun 30, 2024 | $13.20 | -96.5% |
| Q2 FY2023 | Jun 30, 2023 | $91.20 | -62.7% |
| Q2 FY2022 | Jun 30, 2022 | $216.00 | -31.8% |
| Q2 FY2021 | Jun 30, 2021 | $475.20 | – |
| Q2 FY2020 | Jun 30, 2020 | $374.40 | – |
| Q2 FY2018 | Jun 30, 2018 | $244.80 | – |
| Q2 FY2017 | Jun 30, 2017 | $316.80 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?